BioSpace News Archive

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, today announced that CEO Amy Trombly and CFO Jerry Dvonch will present at the following upcoming virtual conferences.

Anika Therapeutics, Inc., a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, reported financial results for its fourth quarter and year-ended December 31, 2020.

NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, provided business highlights and reported financial results for the periods ending December 31, 2020.

Evoke Pharma, Inc., a specialty pharmaceutical company focused on treatments for gastrointestinal disorders and diseases, announced that the Company is scheduled to release its fourth quarter and full year 2020 financial results on Thursday, March 11, 2021, after the market closes.

Soliton, Inc., a medical device company with a novel and proprietary platform technology, reported financial results for the fourth quarter and full year ended December 31, 2020.

DURECT Corporation announced financial results for the three months and year ended December 31, 2020 and provided a corporate update.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, reported financial results for the quarter and year ended December 31, 2020.

Danaher Corporation announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will be presenting at the Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 11:30 a.m. ET.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that three abstracts have been accepted for presentation at the 73rd annual meeting of the American Academy of Neurology (AAN), taking place virtually from April 17 through April 22, 2021

PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform designed to provide more effective and safer products, announced today that the Company will release its 2020 fourth quarter financial results on Friday, March 12, 2021